Clinical trials: Relapsed Malignant Mesothelioma, active
Mesothelioma
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
By incorporating a platform trial protocol design, SELECTmeso will spearhead a next-generation precision medicine trial platform in relapsed mesothelioma for the UK enabling early evaluation of hypothesis-driven targeted…
- Trial name
- SELECTmeso (NCT07602946)
- Testing
- BMS-986504
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Southampton
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural…
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Trial name
- NCT01064648
- Testing
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis
- Where
- 230 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Pleural Mesotheliomas
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy.
- Trial name
- Bi-MAPS (NCT06840834)
- Testing
- Ivonescimab
- Where
- 21 sites in France
- Volunteers
- 38 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique